


PHARMACEUTICAL 2018



Neoleukin Therapeutics Inc. Rank 66 of 342





PHARMACEUTICAL 2018





Neoleukin Therapeutics Inc. Rank 66 of 342

The relative strengths and weaknesses of Neoleukin Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neoleukin Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Neoleukin Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 151% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	108,825
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,956
Liabilities, Non-Current	486
Other Assets	599
Other Compr. Net Income	99
Other Expenses	0
Other Liabilities	0
Other Net Income	936
Other Revenues	0
Property and Equipment	905
Research and Development	36,267
Selling, General and Administrative Expense	14,852

Output Variable	Value in 1000 USD
Assets	110,329
Liabilities	11,442
Expenses	51,119
Revenues	0
Stockholders Equity	98,887
Net Income	-50,183
Comprehensive Net Income	-50,134
Economic Capital Ratio	197%

